Market research
IGMS IGM Biosciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 77M
- P/E ratio
- Not available
- Analyst target
- 1.1235
- Dividend yield
- Not available
- Beta
- 0.59
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4495851085
- Market cap
- 77M
- P/E ratio
- Not available
- Analyst target
- 1.1235
- Dividend yield
- Not available
- Beta
- 0.59
About
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IGMS discussion.
5 years, 4 months ago
IGM Biosciences, Inc is currently in a long term uptrend where the price is trading 7.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
IGM Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.5% to $-81K since the same quarter in the previous year.
Finally, its free cash flow fell by 132.7% to $-29M since the same quarter in the previous year.
Based on the above factors, IGM Biosciences, Inc gets an overall score of 3/5.